Allergan, FDA fight eyelash-mad copycats

It looks like a drug, it acts like a drug, but if comes in a cosmetics tube instead of an eyedropper, is it still a drug?

Call it the case of the thicker-lashed glaucoma patient. Lumigan, a glaucoma remedy sold by Allergan, has the unusual added benefit of promoting eyelash growth. Some eye docs are prescribing it not only to glaucoma patients, but off-label for cosmetics use. Meanwhile, an entrepreneurial cosmetics maker allegedly used similar ingredients in a mascara-like package. The FDA seized raided the company and seized boxes of the product on Friday, calling it a "mislabeled drug."

Meanwhile, Allergan itself is rumored to be testing Lumigan for cosmetic use. And it has sued seven cosmetics companies for patent infringement. Of course, the company has plenty of experience pushing medical remedies into the profitable cosmeceuticals realm. Remember Botox?

- check out the Wall Street Journal article

Related Articles:
Allergan wins FDA OK for new therapy. Report
Allergan injects $370M into Esprit buyout. Report
Allergan buying Groupe Corneal. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.